MIRA Pharmaceuticals Announces New Preclinical Findings Showing That Ketamir-2, Oral Ketamine Analog, Achieves 60% Greater Efficacy Than FDA-Approved Neuropathic Pain Treatment Gabapentin In Reducing Chemotherapy-induced Pain
Portfolio Pulse from Benzinga Newsdesk
MIRA Pharmaceuticals has announced new preclinical findings indicating that their oral ketamine analog, Ketamir-2, is 60% more effective than the FDA-approved neuropathic pain treatment Gabapentin in reducing chemotherapy-induced pain.
October 28, 2024 | 11:43 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
MIRA Pharmaceuticals' Ketamir-2 shows promising preclinical results, outperforming Gabapentin by 60% in efficacy for chemotherapy-induced pain.
The announcement of Ketamir-2's superior efficacy compared to Gabapentin is significant for MIRA Pharmaceuticals as it suggests a potential competitive advantage in the neuropathic pain treatment market. This could lead to increased investor interest and a positive impact on MIRA's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100